263 related articles for article (PubMed ID: 14565810)
1. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.
Kabadi MU; Kabadi UM
Ann Pharmacother; 2003 Nov; 37(11):1572-6. PubMed ID: 14565810
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
Johnson JL; Wolf SL; Kabadi UM
Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
[TBL] [Abstract][Full Text] [Related]
3. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
[TBL] [Abstract][Full Text] [Related]
4. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
6. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
Olsson PO; Lindström T
Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
[TBL] [Abstract][Full Text] [Related]
7. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
Ebato C; Shimizu T; Arakawa M; Mita T; Fujitani Y; Watada H; Kawamori R; Hirose T
Diabetes Res Clin Pract; 2009 Oct; 86(1):31-6. PubMed ID: 19692134
[TBL] [Abstract][Full Text] [Related]
8. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus.
Kawamori R; Eliaschewitz FG; Takayama H; Hayashida CY
Diabetes Res Clin Pract; 2008 Jan; 79(1):97-102. PubMed ID: 17919763
[TBL] [Abstract][Full Text] [Related]
11. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
Ross SA; Zinman B; Campos RV; Strack T;
Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes.
Kabadi UM; Kabadi M
Diabetes Res Clin Pract; 2006 Jun; 72(3):265-70. PubMed ID: 16406190
[TBL] [Abstract][Full Text] [Related]
14. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
Kabadi UM; Kabadi MU
J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Luis Bautista J; Bugos C; Dirnberger G; Atherton T
Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
Rosenkranz B
Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
[TBL] [Abstract][Full Text] [Related]
17. Hypoglycemia in hospitalized patients treated with sulfonylureas.
Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
[TBL] [Abstract][Full Text] [Related]
18. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
[TBL] [Abstract][Full Text] [Related]
19. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
20. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Langtry HD; Balfour JA
Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
